Table 3 Comparison of patients with lower (< median) and higher (> median) MethScore
Training cohort (n = 128) | Testing cohort (n = 50) | ||||||
|---|---|---|---|---|---|---|---|
Low MethScore (n = 64) | High MethScore (n = 64) | p value | Low MethScore (n = 35) | High MethScore (n = 15) | p value | ||
ELN 2017 | Favorable | 14 | 4 | 0.004 | 13 | 6 | 1.000 |
Intermediate | 36 | 31 | 13 | 5 | |||
Adverse | 8 | 20 | 9 | 4 | |||
NA | 6 | 9 | 0 | 0 | |||
Sex | Male/Female | 34/30 | 34/30 | 1.000 | 19/16 | 5/10 | 0.224 |
Transplantation in 1st CR | Yes/No/NA | 36/28/0 | 21/43/0 | 0.012 | 16/19/0 | 2/13/0 | 0.052 |
Relapse | 20/44/0 | 22/42/0 | 0.851 | 15/20/0 | 8/7/0 | 0.548 | |
CR after 1st induction | 44/19/1 | 26/37/1 | 0.002 | 23/12/0 | 11/4/0 | 0.746 | |
FLT3-ITD | Positive/Negative/NA | 14/49/1 | 18/46/0 | 0.541 | 7/28/0 | 6/9/0 | 0.170 |
DNMT3A mutation | 17/40/7 | 23/33/8 | 0.242 | 5/30/0 | 5/10/0 | 0.143 | |
IDH1/2 mutation | 12/45/7 | 14/42/8 | 0.660 | 7/28/0 | 0/15/0 | 0.087 | |
TET2 mutation | 4/49/11 | 7/42/15 | 0.346 | 2/33/0 | 2/13/0 | 0.574 | |
ASXL1 mutation | 4/49/11 | 5/44/15 | 0.735 | 2/33/0 | 3/12/0 | 0.152 | |
NRAS mutation | 8/45/11 | 9/40/15 | 0.184 | 9/26/0 | 4/11/0 | 1.000 | |
TP53 mutation | 0/55/9 | 12/43/9 | < 0.001 | 2/33/0 | 1/14/0 | 1.000 | |
NPM1 mutation | 22/40/2 | 21/40/3 | 1.000 | 14/21/0 | 7/8/0 | 0.759 | |
CEBPA mutation | 4/59/1 | 4/55/5 | 1.000 | 2/33/0 | 1/14/0 | 1.000 | |
RUNX1 mutation | 4/49/11 | 5/44/15 | 0.735 | 1/34/0 | 1/14/0 | 0.514 | |
Number of mutations | Average ± SD/Median | 1.7 ± 1.3/1.5 | 2.3 ± 1.7/2.0 | 0.099 | 1.8 ± 1.2/2.0 | 2.5 ± 1.8/3.0 | 0.161 |
Age | 45.5 ± 13.4/44.0 | 55.1 ± 10.0/58.3 | < 0.001 | 54.1 ± 14.4/59.0 | 58.9 ± 12.1/60.0 | 0.285 | |
Leukocytes | 63.6 ± 39.3/61.0 | 69.4 ± 40.4/70.0 | 0.400 | 48.1 ± 59.1/19.9 | 51.4 ± 63.9/29.0 | 0.751 | |